“参阳”方辅助治疗口腔鳞状细胞癌的远期疗效评价  

Long Term Follow-up Results of Chinese Prescription"Shen Yang"in the Combined and Sequential Treatment of Oral Squamous Cell Carcinoma

作　　者：林国础[1] 邱蔚六[1] 陆昌语[2] 郭一钦[3] 曹阳[2] Walter.Guralnick Chung-Cheng.Hsich Thomas Albert Williarm C.Wood Edward Everts 

机构地区：[1]上海第二医科大学附属第九人民医院口腔医学院口腔颌面外科,上海200011 [2]上海第二医科大学附属第九人民医院口腔医学院口腔免疫教研室,上海200011 [3]上海第二医科大学附属第九人民医院口腔医学院中医科,上海200011 [4]美国麻省总医院 [5]美国哈佛大学公共卫生学院 [6]美国阿勒冈健康科学大学

出　　处：《上海口腔医学》2003年第5期321-323,共3页Shanghai Journal of Stomatology

摘　　要：目的本研究旨在进一步评价综合序列治疗中加用中药“参阳”方对口腔鳞状细胞癌(简称鳞癌)患者的远期疗效。方法本组病例系初发口腔鳞癌患者,共238例。随机分为治疗组(参阳方)与对照组(安慰剂)。剔除术后未服满中药3个月患者17例,术后失访8例,实际研究病例数213例。其中治疗组104例,对照组109例。全组病例均经过5～10a以上随访(随访率为96.44%)。数据用Logrank法进行统计分析。结果“参阳”方组的3、5、8、10a生存率分别较对照组提高8.46%、9.26%、9.04%、8.57%,经统计学处理,P=0.1936,P>0.05,实际数据有延长生存率的趋势。结论术后服中药“参阳”方,有明显提高口腔鳞癌患者生存率的趋向,可作为综合序列治疗的辅助方法之一。Objective To evaluate the long term therapeutic effect of Chinese prescription'Shen Yang'in the combined and sequential therapy for oral squamous cell carcinoma cases.Methods There are238cases with oral squamous cell carcinoma.They were divided into two groups randomly as'Shen Yang'experiment group and control group(placebo).25cases were preduded from the experimentgroup.17of them were due to unexperiment of taking'Shen Yang'within three months.8cases were lost of follow-up.213patients were included in this study.Among them,104cases in experiment group,and109cases in control one.Patients in both groups were followed-up for5～10years.Their life-curve was calcu-lated by means of Logrank method.Results The survival rate of'Shen Yang'group was improved by8.46%,9.26%,9.04%and8.57%for3-year,5-year,8-year and10-year survival rates.But the differences between the two groups were not statistically significant(P=0.1936,P>0.05).Conclusion Chinese prescription of'Shen Yang'had a tendency to im-prove the survival rafe for oral squamous cell carcinoma patients.

关 键 词：口腔肿瘤 鳞状细胞癌 中草药 治疗 

分 类 号：R739.8[医药卫生—肿瘤]